# US 2008/0076146 A1 · Method for selecting therapeutic agents for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076146 A1
- Document ID: US20080076146A1
- Status: Published application
- Kind: A1
- Application number: 11/944,884
- Filed: 2007-11-26
- Published: 2008-03-27
- Earliest claimed: 1996-07-12
- Assignees: Precision Therapeutics, Inc.
- Inventors: Paul Kornblith
- Web page: https://patentgrep.com/patent/US20080076146A1

## CPC

- G01N 33/5044: {involving specific cell types}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5014: {for testing toxicity}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. With respect to the culturing of malignant cells, for example, it is believed (without any intention of being bound by the theory) that by maintaining the malignant cells within a multicellular particulate of the originating tissue, growth of the malignant cells themselves is facilitated versus the overgrowth of fibroblasts or other cells which tends to occur when suspended tumor cells are grown in culture. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. Growth of cells is monitored to ascertain the time to initiate the assay and to determine the growth rate of the cultured cells; sequence and timing of drug addition is also monitored and optimized. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.

## Claims

### Claim 1

A method for assessing chemosensitivity of patient cells comprising the steps of:
a) harvesting a specimen of a patient's tissue, cells ascites, or effusion fluid;
b) separating said specimen into multicellular particulates;
c) growing a tissue culture monolayer from said cohesive multicellular particulates;
d) inoculating cells from said monolayer into a plurality of segregated sites; and
e) treating said plurality of sites with at least one active agent, followed by assessment of chemosensitivity of the cells in said site to at least one active agent.

### Claim 2 (depends on 1)

The method according to claim 1 wherein step a) further comprises the step of
a) preparing a specimen which was harvested from a sample of patient tumor tissue.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said plurality of segregated sites further comprises a plate containing a plurality of wells therein.

### Claim 4 (depends on 1)

The method according to claim 1 wherein step e) further comprises the step of:
e) treating said plurality of sites with a plurality of active agents at varied concentrations, followed by assessment of optimal chemosensitivity with respect to a single active agent at a single concentration.

### Claim 5 (depends on 1)

The method according to claim 1 wherein step e) further comprises the step of:
e) treating said plurality of sites with a plurality of active agents over a length of time adequate to permit assessment of both initial cytotoxic effect and longer-term inhibitory effect of at least one of said plurality of active agents.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the chemosensitivity assayed according to step e) is anti-cancer sensitivity.

### Claim 7 (depends on 1)

The method according to claim 1 wherein step d) is accomplished using a Terasaki dispenser.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the cells in step d) are prepared in suspension prior to inoculation into a plurality of wells in a culture plate.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said active agent is a chemotherapeutic agent.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said active agent is a wound healing agent.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said active agent is a radiation therapy and/or a radiation therapy sensitizing or ameliorating agent.

### Claim 12 (depends on 1)

The method according to claim 1, where said active agent is an immunotherapeutic agent.
